Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

619 results about "Fucose" patented technology

Fucose is a hexose deoxy sugar with the chemical formula C₆H₁₂O₅. It is found on N-linked glycans on the mammalian, insect and plant cell surface. Fucose is the fundamental sub-unit of the seaweed polysaccharide fucoidan. The α(1→3) linked core of fucose is a suspected carbohydrate antigen for IgE-mediated allergy.

Genetically engineered bacterium for synthesizing fucosyllactose as well as preparation method and application of genetically engineered bacterium

The invention provides a genetically engineered bacterium for synthesizing fucosyllactose as well as a preparation method and application of the genetically engineered bacterium. The genetically engineered bacterium is prepared by knocking out a glucose-1-phosphate undecanoate transferase gene wcaJ and a beta-galactosidase gene lacZ on the basis of an original strain, the invention relates to an overexpression gene of a phosphomannose gene manB, a phosphoguanine transferase gene manC, a GDP-mannose-4, 6-dehydratase gene gmd, a GDP-fucose synthetase gene WcaG and a beta-galactoside permease gene lacY, and further, the overexpression gene of an alpha-1, 2-fucosyltransferase or an alpha-1, 3-fucosyltransferase is also used for the overexpression of a phosphomannose gene manB, a phosphoguanine transferase gene manC, a GDP-mannose-4, 6-dehydratase gene gmd, a GDP-fucosyltransferase gene. According to the invention, the modified Escherichia coli probiotic Nissle1917 is preferably used as a host for biosynthesis of fucosyllactose, no endotoxin hidden danger exists, and a foundation is laid for industrial production of fucosyllactose.
Owner:BY HEALTH CO LTD

Application of breast milk oligosaccharide to improvement of intestinal flora of mothers and infants

The invention relates to application of breast milk oligosaccharides to improvement of intestinal flora of mothers and infants, in particular to application of 2 '-fucosyllactose to preparation of food which is taken by a mother and contributes to regulation of intestinal flora of the mother and offspring thereof, and the mother is in a gestation period and / or a lactation period. The invention is provided through a large amount of research; when a mother supplements a certain amount of 2 '-fucosyllactose in a gestation period and / or a lactation period, the abundance of beneficial bacteria in intestinal tracts of the mother can be remarkably improved, the content of harmful bacteria is reduced, meanwhile, the abundance of beneficial bacteria in intestinal tracts of filial generations of the mother is remarkably improved, and the content of harmful bacteria is reduced; particularly, the abundance of some beneficial bacteria which cannot be directly eaten in the intestinal tracts of the mother and the offspring can be adjusted.
Owner:FEIHE (JILIN) DAIRY CO LTD +1

Infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as preparation method and application of infant formula milk powder

The invention provides infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the infant formula milk powder. The invention provides infant formula milk powder for the first time, the infant formula milk powder comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The infant formula milk powder can improve intestinal inflammation and / or microbial disorder.
Owner:INNER MONGOLIA YILI IND GROUP CO LTD

Application of fucoidin degrading enzyme OUC-MgFucD1 in preparation of fucoidin oligosaccharide

The invention discloses application of fucoidin degrading enzyme OUC-MgFucD1 in preparation of fucoidin oligosaccharide, and belongs to the technical field of preparation of the fucoidin oligosaccharide. The amino acid sequence of the fucoidin degrading enzyme OUC-MgFucD1 is as shown in SEQ ID NO. 1, and the fucoidin degrading enzyme OUC-MgFucD1 is as shown The fucose oligosaccharide is fucose, fucodisaccharide and fucotriose, the molecular formula of the fucose is C6H12O8S, the molecular formula of the fucodisaccharide is C12H22O15S2, and the molecular formula of the fucotriose is C18H32O16S. The invention further discloses a preparation method of the fucose oligosaccharide. The fucoidin degrading enzyme OUC-MgFucD1 disclosed by the invention can specifically act on fucoidin, and a specific fucoidin oligosaccharide combination is generated by precisely cutting a main chain glucosidic bond of the fucoidin. The invention provides a key technical support for the development of high-added-value fucoidan oligosaccharide products, and has important significance for promoting the industrial application of the fucoidan oligosaccharide in the fields of functional foods, biological medicines and the like.
Owner:OCEAN UNIV OF CHINA

Application of ganoderma lucidum strain SS30 in preparation of products for treating cancers

The invention discloses application of a ganoderma lucidum strain SS30 in preparation of a product for treating cancers, and belongs to the technical field of biology. The invention provides ganoderma lucidum strain SS30 mycelium polysaccharide. The ganoderma lucidum strain SS30 mycelium polysaccharide is prepared from glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose and lacturonic acid. The polysaccharide has a remarkable effect of inhibiting transplantable pancreatic cancer and primary colorectal cancer, can achieve the effect of treating cancer by improving the immune function and reducing the oxidation product generation level, provides a new material for development and utilization of lucid ganoderma and products thereof, and has a wide application prospect. And a research basis is provided for research and development of cancer-related drugs and research of a cancer treatment mechanism.
Owner:ANHUI SPRY BIOTECHNOLOGY CO LTD +1

Use of nutritional compositions to modulate brain immunity

The invention belongs to the field of nutrient substance research, and particularly relates to application of a nutrient composition to regulation of brain immunity. The invention provides application of a nutritional composition in preparation of food for regulating brain immunity. Wherein the nutritional composition comprises the following necessary components: lactoferrin and fucosyllactose, and in the nutritional composition, the mass ratio of the lactoferrin to the fucosyllactose is 1: (0.1-30). Research finds that after lactoferrin and fucosyllactose are combined according to a certain proportion, the lactoferrin and fucosyllactose have a synergistic effect of regulating brain immunity. Experimental data show that after the combination of lactoferrin and fucosyllactose is used for treating the BV2 cells, the trend that the BV2 cells are differentiated into M2 phenotype microglial cells is higher than the trend that the BV2 cells are differentiated into M1 phenotype microglial cells, and the amount of secreted inflammatory factors is obviously reduced.
Owner:HEILONGJIANG FEIHE DAIRY CO LTD +1

Application of 2 '-fucosyllactose in preparation of immune balance medicine or food

The invention relates to 2 '-fucosyllactose, in particular to application of the 2'-fucosyllactose to preparation of immune balance drugs or food. The immune balance comprises regulation and control of the ratio of Th17 cells to Treg cells of Th17 / Treg immune imbalance offspring activated by maternal immune or induced by virus infection; according to the application disclosed by the invention, the fact that filial generations generated after the maternal body of a mammal generates immune reaction activation can regulate and control the proportion of Th17 and Treg cells through the influence of 2 '-fucosyllactose on intestinal flora is found, so that Th17 and Treg immune balance is realized; in addition, social and cognitive disorders and repetitive behaviors related to filial generation autism induced by Th17 / Treg immune imbalance can be improved.
Owner:BIOSTIME (CHANGSHA) NUTRITION FOOD CO LTD

Nutritional composition comprising GOS and HMO

The present invention relates to a combination of a mixture of galactooligosaccharides (GOS) and human milk oligosaccharides (HMO), or a nutritional composition comprising such a combination. The combination or composition is useful for the treatment and / or prevention of stress and / or mood disorders in infants, toddlers and / or children. The mixture of HMO consists of or consists essentially of 2 '-fucosyllactose (2' FL) and difucosyllactose (DFL) or lactose-N-tetrasaccharide (LNT) and 6 '-sialyllactose (6' SL). The invention also relates to the use of a combination of a mixture of galactooligosaccharides (GOS) and human milk oligosaccharides (HMO) or a composition comprising such a combination for the treatment and / or prevention of stress and / or mood disorders in infants, toddlers and / or children, wherein the mixture of HMO consists of or consists essentially of 2 '-fucosyllactose (2' FL) and difucosyllactose (DFL) or lactose-N-tetrasaccharide (LNT) and 6 '-sialyllactose (6' SL).
Owner:SOCIETE DES PRODUITS NESTLE SA

Composition for improving bone density and application thereof

The invention discloses a composition for improving bone density and application thereof, and belongs to the technical field of food. According to the invention, the 1, 3-dioleic acid-2-palmitin, the osteopontin and the oligosaccharide are compounded for use, and the components interact to promote mutual absorption and utilization, so that the growth and development of bones in the growth period of infants are improved, the mineral content and the bone mineral density of the bones are increased, the health of the bones is promoted, and the composition is safe and free of side effects. And by optimizing the variety of the oligosaccharide, the compound use of the galactooligosaccharide and the 2 '-fucosyllactose is found to be capable of better improving the growth and development of bones in the growth period of the infants.
Owner:BIOSTIME GUANGZHOU HEALTH PROD +1

Normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and preparation method thereof

The invention discloses a normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and a preparation method thereof. The invention belongs to the technical field of biological medicine. The structure of the room-temperature bacterial liquid protection microcapsule is as follows: an inner layer is an activity maintaining layer and mainly consists of a sodium alginate-calcium chloride polyelectrolyte compound (the thickness is 50-100 microns); the middle layer is a pH response release layer and is mainly composed of hydroxypropyl methyl cellulose phthalate (HPMCP, dissolved at pH of 6.8 or above) and nano calcium carbonate particles (the particle size is 50nm, and the proportion is 10% w / w); the outer layer is a mucous membrane adhesion layer, and the main components of the mucous membrane adhesion layer comprise fucose modified chitosan (Fuc-CS, targeted colonic mucous membrane lectin protein) and carbomer 940 (pH sensitive adhesion polymer); the method is a microcapsule capable of preserving the bacterial liquid at normal temperature and accurately targeting colon release and adhesion colonization and a process thereof, the problem of flora activity loss caused by a freeze-drying process can be solved, in addition, the process does not need freeze-drying equipment, and the production cost is reduced.
Owner:BEIJING QINGSONG JINGCHUANG BIOTECHNOLOGY CO LTD

Composition for simulating whole breast milk oligosaccharide and application thereof

The invention belongs to the technical field of nutritious food, and discloses a composition for simulating whole breast milk oligosaccharide and application of the composition. In the composition for simulating the whole breast milk oligosaccharide, the mass ratio of 2 '-fucosyllactose to lactose-N-neotetraose to 3'-sialyllactose is (3.9-8.1): (0.8-1.2): (0.8-1.2), and the breast milk oligosaccharide 2 '-fucosyllactose, the lactose-N-neotetraose and the 3'-sialyllactose are mutually matched to take effect in a synergistic manner, so that the whole breast milk oligosaccharide is obtained. The composition can improve the memory ability and cognitive ability of an eating object, can be added into infant food (including infant formula powder, complementary food and nutritional supplements) and nutritional supplements or food of children over 3 years old, teenagers and aged people, and has a wide application prospect.
Owner:NANCHANG UNIV

Application of breast milk oligosaccharide in regulating brain immunity

The invention belongs to the technical field of food, and relates to application of breast milk oligosaccharide in regulating brain immunity. Specifically, the invention relates to the non-therapeutic purpose of adjusting brain immunity by adjusting polarization of microglial cells M1 / M2, and the breast milk oligosaccharide is any one of 3-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3 '-sialic acid lactose and 6'-sialic acid lactose. Research results show that a specific variety of breast milk oligosaccharides (especially 3-FL) can obviously inhibit the generation of neurotoxic factors NO, inflammatory factors TNF-alpha and IL-1beta in microglial cells, and promote the generation of anti-inflammatory cytokines IL-10 in the microglial cells, so that the state of the microglial cells is improved, damage repair is promoted, and the microglial cells are prevented from being damaged. Therefore, the effect of regulating brain immunity is achieved.
Owner:HEILONGJIANG FEIHE DAIRY CO LTD +1

Method for removing lactulose-based isomer in oligosaccharide separation and purification process

The invention relates to the technical field of biology, and particularly discloses a method for removing lactulose-based isomers in an oligosaccharide separation and purification process. The method comprises the following steps: taking oligosaccharide fermentation liquor for producing oligosaccharide through fermentation by using lactose as a substrate, sequentially carrying out thallus removal, decoloration, electrodialysis desalination, ion exchange resin desalination, concentration, sequential simulated moving bed chromatographic purification, ultrafiltration, re-concentration and spray drying, and detecting the oligosaccharide and the lactulose-based isomer in the oligosaccharide. According to the method disclosed by the invention, the content of lactulose-based isomers in the separation and purification process is greatly reduced, so that the product purity is effectively improved; the method can be applied to the synthesis process of other milk oligosaccharides such as fucose lactose (FL), lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT), lactose-N-fucopentasaccharide (LNPFI) and the like or other carbohydrates containing a lactosyl group, has a very high application value, and accords with laws and regulations.
Owner:HEFEI INSTITUTE OF PHYSICAL SCIENCE CHINESE ACADEMY OF SCIENCES

Composition for promoting bone health and bone formation as well as application and product thereof

The invention provides a composition for promoting bone health and bone formation as well as application and a product thereof, and belongs to the field of foods. The composition disclosed by the invention is prepared from the following components in parts by weight: 1 to 5 parts of osteopontin, 1 to 50 parts of 2 '-fucosyllactose and 0.05 to 50 parts of a calcium source. The composition disclosed by the invention shows a relatively good synergistic effect in promoting calcium absorption, and can be used for improving bone density, preventing and treating osteoporosis and the like.
Owner:BIOSTIME (CHANGSHA) NUTRITION FOOD CO LTD

An active Inonotus obliquus polysaccharide IOP-1 against non-small cell lung cancer and its application

The present invention discloses an anti-non-small cell lung cancer active birch inonotus polysaccharide IOP-1 and its application, belonging to the field of biomedicine. The present invention adopts a method of boiling water extraction and ethanol precipitation of birch inonotus polysaccharide, and combines DEAE cellulose column purification technology, and utilizes the principle that macromolecular polysaccharides are insoluble in organic solvents to successfully achieve the separation of birch inonotus polysaccharide and obtain a birch inonotus polysaccharide IOP-1 with anti-non-small cell lung cancer activity, wherein the monosaccharide composition of the birch inonotus polysaccharide IOP-1 includes fucose, rhamnose, arabinose, galactose, glucose, xylose and mannose with a molar mass ratio of 2.41:0.58:1.03:2.17:82.20:4.33:7.29. Its significant effect against non-small cell lung cancer was verified by in vitro and in vivo experiments, providing a new treatment method for the clinical treatment of non-small cell lung cancer.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Children formula food for improving intestinal inflammation and / or microbial disorder as well as preparation method and application of children formula food

The invention provides a children formula food for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the children formula food. The invention firstly provides the infant formula food, the infant formula food is infant formula food or child formula food, the infant formula food comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The children formula food can improve intestinal inflammation and / or microbial disorder.
Owner:INNER MONGOLIA YILI IND GROUP CO LTD

GDP-fucose synthase polypeptide and application thereof

The invention relates to a series of GDP-fucose synthase polypeptides which can be applied to synthesis of GDP-fucose which is a precursor of human milk oligosaccharides (HMOs), and belongs to the technical field of enzyme engineering. In certain embodiments, the polypeptide capable of catalyzing the conversion of GDP-4-keto-6-deoxymannose into GDP-fucose comprises a polypeptide of which the amino acid sequence is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to the amino acid sequence of SEQ ID NO: 1 and / or the amino acid sequence of the polypeptide M1-14. The invention provides a series of polypeptides for synthesizing GDP-fucose.
Owner:HENRUI (QINGDAO) BIOTECH CO LTD

Nutritional composition comprising breast milk oligosaccharides and probiotics for improving depression and use thereof

The invention belongs to the field of food, and particularly relates to a nutritional composition containing breast milk oligosaccharide and probiotics for improving depression and application of the nutritional composition. The invention provides application of a nutritional composition in preparation of food beneficial to improving constipation and anxiety state and / or depression state caused by constipation. Wherein the nutritional composition comprises the following components (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, and (ii) a bifidobacterium probiotic; the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the bifidobacterium probiotics at least comprise bifidobacterium longum subsp. Longum. According to the present invention, the substance combination of the neutral fucosylated breast milk oligosaccharide and the bifidobacterium probiotic can improve the abnormal brain-intestine interaction, such that the constipation can be easily improved, and the anxiety and depression state caused by the constipation can be easily improved;
Owner:HEILONGJIANG FEIHE DAIRY CO LTD +2

Nutritional compositions of oligosaccharides and probiotics and uses thereof

The invention belongs to the field of food, and particularly relates to a nutritional composition of oligosaccharide and probiotics and application of the nutritional composition. The invention provides application of a nutritional composition in preparation of food beneficial to improvement of constipation and improvement of cognitive competence decline caused by constipation. Wherein the nutritional composition comprises the following components (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, and (ii) a bifidobacterium probiotic; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the bifidobacterium probiotics at least comprise bifidobacterium longum subsp. Longum. According to the present invention, with the substance combination of the neutral fucosylated breast milk oligosaccharide and the bifidobacterium probiotic, the abnormal brain-intestine interaction can be improved, such that the constipation can be easily improved, and the cognitive ability reduction caused by the constipation can be easily improved;
Owner:FEIHE (AR HORQIN BANNER) DAIRY CO LTD +1

Double-encapsulated lipid nanoparticles entering brain through nose as well as preparation method and application of double-encapsulated lipid nanoparticles

PendingCN120617545ANervous disorderKetone active ingredientsOlfactory Epithelial CellDrug encapsulation
The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.
Owner:CHINA NAT TOBACCO QUALITY SUPERVISION & TEST CENT

Engineering escherichia coli for producing L-fucose and application thereof

The invention relates to engineering Escherichia coli for producing L-fucose and application of the engineering Escherichia coli, the production of the L-fucose is enhanced through a metabolic engineering strategy by utilizing a mode of combining genome integration and plasmid expression path genes, and the efficient production of the L-fucose is realized by optimizing a double-plasmid system and enhancing precursor supply. In addition, a hok / sok system and a cysC auxotroph system are introduced, and the plasmid-based engineering strain without antibiotic dependence is successfully constructed. The strain produces 7.99 g / L of L-fucose and 61.91 g / L of L-fucose through shake-flask culture and fed-batch culture under the condition that antibiotics are not added, the highest L-fucose yield reported so far is provided, and the use of antibiotics is completely not needed in the fermentation process.
Owner:JIANGNAN UNIV

Trametes gallica polysaccharide, its preparation method and application in preparing immunomodulatory drugs

The present invention discloses a preparation method of Inonotus hispidus polysaccharide IHP-1aa: It is obtained by removing fat with ethanol, extracting with water and precipitating with ethanol, then removing proteins by the Sevage method, separating neutral polysaccharide components through a DEAE-52 cellulose column and a DEAE agarose gel column, and finally purifying with Sephadex G-100. The Inonotus hispidus polysaccharide has uniform purity and clear composition, and is a heteropolysaccharide composed of glucose, galactose, mannose, fucose and methylgalactose, with a molecular weight of 26.9 kDa. In vitro experiments show that it has no adverse effects on normal cells, can significantly stimulate macrophages RAW264.7 to secrete NO, IL-6 and TNF-α, has good immunomodulatory activity, and can be used for the development of immunomodulatory products.
Owner:HENAN UNIVERSITY

The invention relates to 2apos; method for analyzing carbohydrates in fucosyllactose product

The invention relates to the technical field of fermentation engineering, in particular to a method for analyzing carbohydrates in a 2 '-fucosyllactose product. The carbohydrate analysis method comprises the following steps: aiming at a 2 '-fucosyllactose product, separating carbohydrates through ion exchange chromatography, and the conditions are as follows: a mobile phase A comprises 4-6mM NaOH and 1-3mM NaAC; the mobile phase B is prepared from 80 to 120 mM of NaOH and 80 to 120 mM of NaAC; the elution procedure is a specific gradient elution procedure. According to the carbohydrate analysis method of the 2 '-fucosyllactose product, provided by the invention, miscellaneous sugar with relatively high similarity with the 2'-fucosyllactose in the 2 '-fucosyllactose product can be effectively separated, so that the analysis efficiency and accuracy of carbohydrates in the 2'-fucosyllactose product can be effectively improved; the method has important significance in the related production field of 2 '-fucosyllactose.
Owner:CABIO BIOTECH (WUHAN) CO LTD

Ganoderma tsugae polysaccharide with effect of relieving colorectal cancer as well as preparation method and application of ganoderma tsugae polysaccharide

The invention discloses ganoderma tsugae polysaccharide with a colorectal cancer relieving effect and a preparation method and application thereof, and belongs to the technical field of biological medicine. The ganoderma tsugae polysaccharide is prepared from mannose, glucose, galactose and fucose, the molar ratio of the mannose to the glucose to the galactose to the fucose is 3.221 to 1.414 to 80.539 to 14.826, and the molecular weight of the ganoderma tsugae polysaccharide is 7.056 kDa. It is proved that the ganoderma tsugae polysaccharide can significantly reduce the number and size of colon tumors; the pathological symptoms such as colon weight index, bleeding, crypt budding, dysplasia and hyperplasia are relieved; compared with the prior art, the ganoderma tsugae polysaccharide provided by the invention has the advantages that the ganoderma tsugae polysaccharide can obviously inhibit the levels of IFN-gamma, TGF-beta and IL-17A in colon and also can obviously inhibit the levels of IFN-gamma, TGF-beta and IL-17A in colon, and meanwhile, the level of IL-4 is improved, so that the ganoderma tsugae polysaccharide provided by the invention has an outstanding action effect in the aspect of relieving colorectal cancer, and a theoretical support is provided for developing colorectal cancer medicines with effectiveness and biological safety.
Owner:JILIN AGRICULTURAL UNIV

Application of nutritional composition for assisting in improving memory ability

The invention belongs to the field of food, and particularly relates to application of a nutritional composition for assisting in improving memory ability. The invention provides application of a nutritional composition in preparation of food for assisting in improving memory ability of offspring. The nutritional composition comprises the following necessary components: active folic acid substances and fucosyllactose, moreover, in the nutritional composition, the mass ratio of the active folic acid substance to the fucosyllactose is (0.0001-0.0015): (0.5-10), the food is ingested by a mother to play the role of assisting in improving the memory ability of the offspring, the mother is in a gestation period and / or a lactation period, and the maternal is in the gestation period and / or the lactation period. The filial generation comprises a fetal-stage filial generation and / or an infant-stage filial generation and an optional child-stage filial generation. A large number of studies find that when active folic acid substances and fucosyllactose which are combined according to a certain proportion are supplemented to a mother at the beginning of the gestation period, the memory ability of offspring can be remarkably improved in an auxiliary mode.
Owner:FEIHE (AR HORQIN BANNER) DAIRY CO LTD +1

Antibody conjugates for targeting tumors expressing carcino-embryonic antigens

The present invention relates to antibody conjugates which are particularly suitable for targeting CEA-expressing cells, in particular tumor cells. An antibody conjugate according to the present invention has the structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing CEA; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w'is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus hemiphyllum, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine # imgabs 0 # dimer or a pyrrolo-benzodiazepine # imgabs 1 # dimer (PBD), and analogs or prodrugs thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).
Owner:EMERGING BIOTECHNOLOGY CO

Active inonotus obliquus polysaccharide IOP-1 for resisting non-small cell lung cancer and application of inonotus obliquus polysaccharide IOP-1

The invention discloses inonotus obliquus polysaccharide IOP-1 capable of resisting non-small cell lung cancer activity and application, and belongs to the field of biological medicine. The method for extracting the inonotus obliquus polysaccharide by boiling water and precipitating the inonotus obliquus polysaccharide by ethanol is combined with a DEAE (diethylaminoethanol) cellulose column purification technology, and the principle that macromolecular polysaccharide is insoluble in an organic solvent is utilized, so that the separation of the inonotus obliquus polysaccharide is successfully realized, and the inonotus obliquus polysaccharide IOP-1 with non-small cell lung cancer resisting activity is obtained. The monosaccharide of the inonotus obliquus polysaccharide IOP-1 comprises fucose, rhamnose, arabinose, galactose, glucose, xylose and mannose, wherein the molar mass ratio of the fucose to the rhamnose to the arabinose to the galactose to the glucose to the xylose to the mannose is 2.41: 0.58: 1.03: 2.17: 82.20: 4.33: 7.29. In-vivo and in-vitro experiments prove that the traditional Chinese medicine composition has a remarkable effect of resisting the non-small cell lung cancer, and a novel treatment method is provided for clinical treatment of the non-small cell lung cancer.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Bird's nest sialic acid glycan peptide capable of improving lung inflammation and application of bird's nest sialic acid glycan peptide

The invention discloses cubilose sialic acid glycan peptide capable of improving lung inflammation and application of the cubilose sialic acid glycan peptide. The ratio of fucose modified sugar chains in the cubilose sialic acid glycan peptide is 30-60%, the ratio of sialic acid modified sugar chains in the cubilose sialic acid glycan peptide is 20-40%, the core structure of the fucose type is (HexNAc) 3 (Man) 3 (Fuc) 1, the core structure of the sialic acid type is (HexNAc) 3 (Man) 3 (Gal) 1 (Fuc) 1 (NeuAc) 1, the neutral sugar dissolution rate of the cubilose sialic acid glycan peptide is high, and the glycopeptide shown in SEQ ID NO 2 has a good inflammation improving effect.
Owner:BEIJING RONGSHUTANG BIOTECHNOLOGY CO LTD +1

Recombinant escherichia coli for improving yield of fucosyllactose and construction method and application of fucosyltransferase mutant of recombinant escherichia coli

The invention discloses recombinant escherichia coli capable of increasing the yield of fucosyllactose and a construction method and application of a fucosyltransferase mutant of the recombinant escherichia coli, and belongs to the field of synthetic biology and metabolic engineering. According to the invention, recombinant escherichia coli B20 and B21 are constructed based on key enzyme engineering transformation. Under the shake flask condition, the 3-FL production capacity of the recombinant strain is obviously improved to 6.20 g / L and 6.34 g / L from the initial 3.45 g / L, and the amplification reaches 79.7% and 83.8% respectively. The yields of 3-FL of the strain B20 and the strain B21 respectively reach 53.88 g / L and 54.64 g / L under the culture condition of a 3L fermentation tank. The recombinant escherichia coli for expressing the 2 '-FL is constructed, and the yield of the 2'-FL reaches 64.86 g / L in a 3L fermentation tank. The invention provides a new technical scheme for efficient microbial synthesis of the 3-FL.
Owner:JIANGNAN UNIV

Application of Chinese chestnut non-starch polysaccharide

The invention provides application of non-starch Chinese chestnut polysaccharide, the non-starch Chinese chestnut polysaccharide comprises polysaccharide CNP-1, polysaccharide CNP-2 and polysaccharide CNP-1, the weight-average molecular weight of the polysaccharide CNP-1 is 4.82 * 10 < 3 > kDa, the polysaccharide CNP-1 comprises glucose, galactose, arabinose, rhamnose, fructose, fucose, xylose and glucosamine hydrochloride, the molar ratio of the glucose to the galactose to the arabinose to the rhamnose to the fructose to the fucose to the xylose to the glucosamine hydrochloride is 0.626: 0.121: 0.084: 0.071: 0.061: 0.023: 0.011: 0.003; the polysaccharide CNP-2b has the weight-average molecular weight of 1.25 * 10 < 4 > kDa and comprises glucose, galactose, arabinose, rhamnose, fructose, fucose, xylose and glucosamine hydrochloride according to the molar ratio of (0.505): (0.161): (0.148): (0.077): (0.052): (0.025): (0.027): 0.003; the non-starch polysaccharide can regulate the intestinal flora abundance caused by colitis, improve the intestinal flora structure, maintain the intestinal steady state, relieve the injury degree of colon and ensure the body health.
Owner:HEBEI AGRICULTURAL UNIV.